Back to Market Feed

Product Information

LINZESS 290 MCG CAPSULE is a brand product labeled by Allergan, Inc., priced at $9.0158 per EA under NDC 00456120230. Its NADAC has been published 665 times since Nov 28, 2013.

FDA first approved this application on Aug 30, 2012.

LINZESS 290 MCG CAPSULE

linaclotide
$9.0158per EA

Strength

290 ug/1

Manufacturer

Allergan, Inc.

NDC

00456120230

Classification

Brand

Dosage Form

CAPSULE, GELATIN COATED

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

LINACLOTIDE

Approval Type

New Drug (NDA)

FDA Application

NDA202811

FDA Approved

8/30/2012

On Market Since

9/8/2012

Pharmacological Classes

Guanylate Cyclase Activators
Guanylate Cyclase-C Agonist

Price Statistics

The NADAC for LINZESS 290 MCG CAPSULE has been published 665 times since Nov 28, 2013, and over the history we have for it it has risen 31.0%. The table below summarizes its recorded NADAC range and movement.

Current price$9.0158 per EA
All-time high$18.1590 (May 14, 2025)
All-time low$6.8815 (Nov 28, 2013)
52-week high$18.1469
52-week low$9.0158
Median price$13.5666
Average price$13.1740
Largest weekly change-50.3% (Jan 14, 2026)
Weeks tracked665
Tracking sinceNov 28, 2013

Price History

1W

-0.0%

1M

-0.0%

3M

-0.1%

6M

-0.1%

1Y

-50.3%

3Y

-45.3%

5Y

-39.6%

All

+31.0%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the linaclotide market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

TRULANCE 3 MG TABLET
Brand
65649000330•Salix Pharmaceuticals Inc.
$18.0542
per EA

Frequently asked questions

What is the NADAC price of LINZESS 290 MCG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for LINZESS 290 MCG CAPSULE, manufactured by Allergan, Inc., is $9.0158 per EA (NDC 00456120230), effective Aug 19, 2026.

How has the price of LINZESS 290 MCG CAPSULE changed over time?

Over the history we have for it, the NADAC for LINZESS 290 MCG CAPSULE has risen 31.0%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for LINZESS 290 MCG CAPSULE?

Since Nov 28, 2013, the NADAC for LINZESS 290 MCG CAPSULE has ranged from a low of $6.8815 (Nov 28, 2013) to a high of $18.1590 (May 14, 2025), with a median of $13.5666 per EA.

Are there cheaper alternatives to LINZESS 290 MCG CAPSULE?

No other NADAC-published product currently shares the active ingredient and strength of LINZESS 290 MCG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures LINZESS 290 MCG CAPSULE?

LINZESS 290 MCG CAPSULE (NDC 00456120230) is labeled by Allergan, Inc., and CMS classifies it as a brand product.